Filing Flows › Monte Rosa Therapeutics (GLUE) › Q3 2026
Monte Rosa Therapeutics (GLUE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Monte Rosa Therapeutics (GLUE) reported revenue of $54.4M for the third quarter 2026 (Q3 2026), +326% from a year earlier and +506% from the quarter before. Operating margin was -3.6%, net earnings $3.1M (5.6% of revenue).
Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $54.4M | +506% | +326% |
| Operating profit | −$1.9M | — | — |
| Net earnings | $3.1M | — | — |
| Operating cash flow | −$41.0M | — | -141% |
What changed
Revenue was $54.4M in Q3 2026, up 326% year over year and up 506% from the previous quarter.
Operating costs exceeded revenue by $1.9M, an operating margin of -3.6%. Total costs grew 23% against revenue growth of 326%. The fastest-growing cost line was Research & development (+24%). Net earnings were $3.1M. The effective tax rate was 18.9%. Non-operating items added $5.7M, 151% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$41.0M. Non-cash charges added back $2.9M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items used $53.2M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$42.5M.
Questions
What was Monte Rosa Therapeutics' revenue in the third quarter 2026?
Monte Rosa Therapeutics (GLUE) reported revenue of $54.4M for the third quarter 2026 (Q3 2026), +326% from a year earlier and +506% from the quarter before.
Was Monte Rosa Therapeutics profitable in the third quarter 2026?
Operating loss was $1.9M (-3.6% of revenue) and net earnings $3.1M.